DuPont Acquires Tarsus Pharmaceuticals for $1.1 Billion
Ticker: TARS · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, pharma
TL;DR
DuPont is buying Tarsus for $1.1B cash ($10/share), deal expected Q2 2025.
AI Summary
Tarsus Pharmaceuticals, Inc. announced on March 14, 2025, that it has entered into a definitive agreement to be acquired by E.I. du Pont de Nemours and Company. The transaction is valued at approximately $1.1 billion, with shareholders to receive $10.00 per share in cash. The acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition signifies a major consolidation in the pharmaceutical sector, potentially impacting the development and availability of Tarsus's products and creating opportunities for DuPont's expansion.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of regulatory hurdles or shareholder approval issues.
Key Numbers
- $1.1B — Acquisition Value (Total cash consideration for Tarsus Pharmaceuticals)
- $10.00 — Price Per Share (Cash amount shareholders will receive for each Tarsus share)
Key Players & Entities
- Tarsus Pharmaceuticals, Inc. (company) — Company being acquired
- E.I. du Pont de Nemours and Company (company) — Acquiring company
- $1.1 billion (dollar_amount) — Total acquisition value
- $10.00 (dollar_amount) — Price per share
- March 14, 2025 (date) — Date of definitive agreement
- second quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition of Tarsus Pharmaceuticals by DuPont?
The acquisition is valued at approximately $1.1 billion.
What price per share will Tarsus Pharmaceuticals shareholders receive?
Shareholders will receive $10.00 per share in cash.
Who is acquiring Tarsus Pharmaceuticals?
E.I. du Pont de Nemours and Company is acquiring Tarsus Pharmaceuticals.
When is the acquisition expected to close?
The acquisition is expected to close in the second quarter of 2025.
What is the date of the definitive agreement for the acquisition?
The definitive agreement was entered into on March 14, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding Tarsus Pharmaceuticals, Inc. (TARS).